Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Challenger ( (AU:CGF) ) has shared an announcement.
Challenger Limited has notified the ASX that it has ceased to be a substantial holder in Telix Pharmaceuticals Ltd, formally lodging the required notice under the Corporations Act. The change indicates Challenger and its associated entities have reduced their holding in Telix below the substantial shareholder threshold, signaling a shift in their investment exposure to the biotech company and potentially altering Telix’s institutional shareholder base and governance dynamics.
The most recent analyst rating on (AU:CGF) stock is a Hold with a A$9.50 price target. To see the full list of analyst forecasts on Challenger stock, see the AU:CGF Stock Forecast page.
More about Challenger
Challenger Limited is an Australian financial services group headquartered in Sydney, operating through entities including Challenger Life Company and Challenger Investment Partners. The group focuses on retirement income, investment management, and related financial products and services for Australian investors and institutions, with a presence across major Australian capital cities.
Average Trading Volume: 1,341,780
Technical Sentiment Signal: Buy
Current Market Cap: A$6.36B
For a thorough assessment of CGF stock, go to TipRanks’ Stock Analysis page.